1. Introduction {#sec0005}
===============

Respiratory infection is a common problem in dogs ([@bib0110]). The etiological agents involved in canine infectious respiratory disease are complex. Viral infectious agents include canine distemper virus (CDV), influenza virus, canine herpesvirus (CHV), canine adenovirus 2 (CAV-2), canine parainfluenza virus (CPIV), canine respiratory coronavirus (CRCoV) ([@bib0100]). *Bordetella bronchiseptica* and *Mycoplasma cynos* are the most significant bacterial etiologic agents ([@bib0110], [@bib0130]). Canine distemper (CD) is a highly contagious and fatal disease in dogs caused by CDV. CDV belongs to the *Paramyxoviridae* family. Although live attenuated vaccines have been used for many years to control distemper, CDV continues to cause outbreaks, particularly in young dogs ([@bib0070]). Previous studies reported that vaccinated dogs were infected with CDV in Mexico and Japan ([@bib0145], [@bib0160]). It is therefore necessary to discriminate between wild type and vaccine type strains because the attenuated CDV vaccines are used worldwide. The hemagglutinin (H) gene revealed pronounced genetic diversity and was employed to detect and differentiate between different CDV strains ([@bib0010], [@bib0140], [@bib0160]). There is no specific therapy for animals with canine distemper besides supportive treatment ([@bib0065]). The influenza A virus belongs to the family *Orthomyxoviridae*. The matrix gene is highly conserved and was often used for virus detection ([@bib0085]). Influenza virus causes sustained transmission among dogs, leading to respiratory disease outbreaks, e.g. H3N8 ([@bib0050], [@bib0120]) and H3N2 ([@bib0150]).Treatment with the antiviral medicine oseltamivir has been approved in humans, but its use in dogs still needs evaluation ([@bib0015]). Canine herpesvirus (CHV) is a member of the *Herpesviridae* family. Infection in older dogs appears to be restricted to the upper respiratory tract ([@bib0020]). The CHV glycoprotein B gene is often used as the virus detection target because it is highly conserved ([@bib0060]). Limited studies with antiviral agents such as vidarabine are inconclusive, but immediate recognition and treatment is essential to have any possibility of success ([@bib0055]). *B. bronchiseptica* is a major bacteria cause of kennel cough in dogs. An upstream flagellin gene sequence was employed for specific detection ([@bib0090]). Most *B. bronchiseptica* strains are sensitive to aminoglycosides, extended-spectrum third generation penicillin, tetracycline, quinolone and trimethoprim-sulfamethoxazole ([@bib0105]). *Mycoplasmas cynos* was demonstrated as the only mollicute found associated with canine infectious respiratory disease ([@bib0025]). PCR detection was developed based on its 16S/23S rRNA intergenic spacer (IGS) ([@bib0030]). Treatment with none β-lactam antibiotics such as doxycycline or tetracycline should be effective against most canine mycoplasmas ([@bib0035]).

Infections with mixed respiratory pathogens in dogs are commonly seen and the clinical signs are similar, which makes differential diagnosis necessary ([@bib0025], [@bib0045], [@bib0080], [@bib0100], [@bib0110]). Simultaneous canine vurial respiratory disease detection using multiplex PCR has been reported ([@bib0100]), but the etiogenic bacteria were not involved and the wild and vaccine types of CDVs could not be distinguished. The microarray is a promising alternative that can detect hundreds or thousands of genes in parallel. This study attempts to develop an oligonucleotide microarray system for simultaneous detection and differentiation of dog respiratory pathogens, including wild strains and vaccine strains of CDVs, influenza virus, CHV, *B. bronchiseptica* and *M.cynos.* These pathogens were chosen based on the disease fatality and the particular medicine options. The oligonucleotide microarray could provide an excellent diagnosis approach with better efficacy and efficiency to comprehensively distinguish clinically significant dog respiratory pathogens, including viruses and bacteria at the same time. The proposed device might greatly assist in disease control and therapy.

2. Materials and methods {#sec0010}
========================

The flow chart of experimental design is shown on Supplement Fig. 1.

2.1. Samples {#sec0015}
------------

The wild type CDV (NTU311) and CIV (A/canine/Taiwan/E01/2014) were isolated from the School of Veterinary Medicine, National Taiwan University. The CDV vaccine strains were obtained commercially, including Onderstepoort strain (Nobivac^®^ LDHPPi, Boxmeer, the Netherlands and Fort Dodge^®^ Mas 5-CvK/4L, the Puppyshot^®^ Booster, IA), Distemperoid strain (Nobivac^®^ Canine 1-DAPPvL2 + Cv, NE), Lederle strain (Virbac^®^ Canigen DHAPPiLR, Carros, France), BA strain (Merial^®^ Eurican DHPPI2-L, Lyon, France) and N-CDV strain (Pfizer^®^ Vanguard Plus 5 L4 CV, Lincoln, NE). CHV, CAV-2, CPIV and CRCoV were from the positive clinical samples proven by PCR and sequencing at the Laboratory of Molecular Biology, School of Veterinary Medicine, National Taiwan University. *B.bronchiseptica* was from commercial vaccine (Nobivac^®^ KC, Boxmeer, the Netherlands). *Mycoplasma cynos* (ATCC^®^27544™) was shared from the Agricultural Technology Research Institute, Miao-Li, Taiwan.CAV-2, CPIV and CRCoV were used for specificity test of multiplex PCR and oligonucleotide microarrays as negative controls. Fifty-six nasal swab samples were from 56 dogs that were presented at National Taiwan University Veterinary Hospital from January to October of 2015 and showed clinical respiratory signs.

2.2. Nucleic acid extraction, reverse transcription and uniplex PCR {#sec0020}
-------------------------------------------------------------------

Nucleic acid of the reference pathogens and clinical samples, including both DNA and RNA, was extracted using PetNAD™ Nucleic Acid Co-prep kit (GeneReach Biotechnology Corp., Taiwan) in accordance with the manufacturer's instructions. RNA was further reverse transcribed to DNA using Transcriptor High Fidelity cDNA Synthesis Kit (Roche, Mannheim, Germany) based on the manufacturer's instructions. PCR primers were from original or modification of the published ones and the target genes of CDV, CIV, CHV, *B. bronchiseptica* and *M. cynos* were hemagglutinin gene, matrix gene, glycoprotein B gene, flagellin gene and 16S/23S rRNA IGS region, respectively ([Table 1](#tbl0005){ref-type="table"} ). The uniplex PCR was carried out in a reaction volume of 25 μl containing 2 μl of template, 0.5 μl of each primer (10 μM) and 5 μl of 5× taq Master Mix (Protech, Taipei, Taiwan). The amplification thermal profile for each pathogen is described below. (1) CDV: 94 °C for 3 min, 34× (94 °C for 30 s, 50 °C for 30 s, and 72 °C for 40 s), 72 °C for 5 min; (2) CIV: 94 °C for 2 min, 34× (94 °C for 1 min, 55 °C for 2 min, and 72 °C for 3 min), 72 °C for 10 min; (3) CHV: 94 °C for 3 min, 34× (94 °C for 30 s, 50 °C for 30 s, and 72 °C for 40 s), 72 °C for 5 min; (4) *B. bronchiseptica*: 94 °C for 4 min, 34× (94 °C for 1 min, 57 °C for 30 s, and 72 °C for 40 s), 72 °C for 5 min; (5) *M. cynos*: 94 °C for 5 min, 34× (94 °C for 1 min, 54 °C for 40 s, and 72 °C for 1 min), 72 °C for 5 min. Ten μl PCR products were separated in 2.0% agarose gel, run in 400 ml 0.5× TBE buffer with 20 μl (10 mg/ml) ethidium bromide at 100 V for 50 min and visualized under UV light.Table 1PCR primers used in this study.Table 1PathogenTarget geneNameSequence (5′ → 3′)DirectionProductReferenceCDVHemagglutininCDHF1dCATGGGAACCCTTYGGRGGForward531 bpModified from thesis[a](#tblfn0005){ref-type="table-fn"}CDHR1CATCCCAYACAAAACATTCAAReverseInfluenza virusMatrixM52CCTTCTAACCGAGGTCGAAACGForward245 bp([@bib0085])M253RAGGGCATTTTGGACAAAKCGTCTAReverseCHVGlycoprotein BCHVF2TGGTCTGGAAGCACATATGCForward427 bpThesis[b](#tblfn0010){ref-type="table-fn"}CHVR2TCAGTATGAGCACCATCTCGReverse*B. bronchiseptica*FlagellinFla3mAGGCACCTGCCCCATCTCForward291 bp([@bib0090])Fla2mAGGCTCCCAAGAGAGAAAGGReverse*M. cynos*16S/23S rRNA IGSMyc1CACCGCCCGTCACACCAForward449 bpModified from reference ([@bib0030])Myc2CAAGGCATCCACCAAAAACTCCReverse[^1][^2]

2.3. Multiplex PCR development {#sec0025}
------------------------------

DNA from the reference pathogens and clinical samples were subjected to multiplex PCR, whose reaction solution was prepared the same as the uniplex PCR except that the five pairs of primers were 5′ end-biotinylated and employed at the same time. The multiplex PCR thermal profile was 94 °C for 3 min, 34× (94 °C for 30 s, 50 °C for 30 s, and 72 °C for 40 s), 72 °C for 5 min. Ten μl PCR products were separated in 2.0% agarose gel, run in 400 ml 0.5× TBE buffer with 20 μl (10 mg/ml) ethidium bromide at 100 V for 60 min and visualized under UV light.

2.4. Probe design {#sec0030}
-----------------

Microarray generic probe used to detect each pathogen was designed based on the most conserved sequence within the amplicon amplified by each pair of primers. Probes used to differentiate different CDV types were designed based on the amplicon sequence difference among different types. All of the probes were derived from the alignment and analyses of the nucleotide sequences retrieved from the GenBank, and conducted using the MegAlign program (DNASTAR, Madison, WI). Each probe sequence and its target strains are listed in [Table 2](#tbl0010){ref-type="table"} .Table 2Oligonucleotide microarray probes used in this study.Table 2PathogenNameSequence (5′ → 3′)Target strainsCDVCDVGCCCATTTAGACTAACTACCAAGGGTAGenericCDVW1TTCACTGTKACCCCYCATWild type strains in Taiwan, Japan, South Korea and ChinaCDVW2CCAGGGAGTCGAGTGGAAWild type strains in Japan and South Korea that CDVW1 cannot bindCDVW3TCATCGAGTCCAATGTAGWild type strains in China that CDVW1 cannot bindCDVV1ACATATCACGAAGTGATCATGCGACDV traditional vaccine strains (Onderstepoort, Distemperoid, Lederle and BA strains)CDVV2GGAAGATTTCTTTTACGTACCDV contemporary vaccine strain (N-CDV strain)Influenza virusIVGCAGGCCCCCTCAAAGCCGAGATGenericCHVCHVGGAAGTTGATGCCAGATCTGTTTATCCGeneric*B. bronchiseptica*BbACGGACGCCTGTCCCCGCAGGAA*B. bronchisepticaM. cynos*McGAGAGAACTTTTTTTCTCTCATGTTC*M. cynos*

2.5. Oligonucleotide microarray preparation and hybridization reaction {#sec0035}
----------------------------------------------------------------------

A tail composed of 15 T bases was added onto each 5'end of the oligonucleotide probe, including the positive control probe (an oligonucleotide from capsid protein VP1 of human enterovirus 71 gene, 5′-ATGAAGCATGTCAGGGCTTGGATACCTCG-3′), to enhance the cohesion strength between the probes and microarray substrate. Twenty μM of each probe was then spotted to each specific position on the microarray polymer substrate using DR. Easy spotter (DR. Chip Biotech, Miao-Li, Taiwan) and immobilized using Stratagene UV Stratalinker 1800 (Stratagene, Santa Clara, CA) with 0.6 J. The hybridization reaction between each DNA template and probe was carried out with DR. Chip DIY™ Kit (Dr. Chip Biotech, Miao-Li, Taiwan). The multiplex PCR product was denatured at 95 °C for 5 min and cooled in an ice bath for 5 min. To the microarray chamber was added 200 μl of Hybridization Buffer (containing the 5′ end-biotinylated oligonucleotide complementary to the positive control probe sequence). Two μl of denatured multiplex PCR product was added and incubated at 56 °C with vibration for 1 h. The sample was then washed twice with 250 μl of Washing Buffer at room temperature. The blocking reaction was then performed by mixing 0.2 μl of streptavidin conjugate alkaline phosphatase and 200 μl of Blocking Reagent at room temperature for 30 min, followed with washing twice with Washing Buffer. The colorimetric reaction was then implemented by adding 4 μl of NBT/BCIP and 196 μl of Detection Buffer in the chamber, developing in the dark at room temperature for 5--10 min, and washing twice with distilled water. The hybridization result was read directly with the naked eye.

2.6. Cloning, copy number calculation and detection limit comparison {#sec0040}
--------------------------------------------------------------------

Each uniplex PCR positive signal band on the agarose gel was extracted and purified using GenepHlow™ Gel/PCR Kit (Geneaid, New Taipei City, Taiwan) and then cloned into pGEM-T EasyVector Systems (Promega, Madison, WI) following the manufacturer's instructions. The plasmids were transformed into Max EfficiencyDH5α chemically competent E. Coli (Invitrogen, Carlsbad, CA) which were further cultured on LB agar (Becton Dickson and Company, Sparks, MD). The colonies with successful inserts were confirmed by PCR using plasmid T7 and SP6 primers and then amplified in LB broth (Becton Dickson and Company, Sparks, MD). Plasmid DNA was extracted using Mini Plus™ Plasmid DNA Extraction System (Viogen, Shijr, Taiwan). The inserts were further sequenced using commercial service (Mission Biotech, Taipei, Taiwan). The obtained sequence was further checked using BLAST (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) to confirm nucleotide correctness. The plasmid DNA of CHV, *B. bronchiseptica* and *M. cynos* was quantified with a spectrophotometer (GeneQuant II, Pharmacia, Uppsala, Sweden). The DNA copy numbers were calculated and the DNA was diluted serially in TE buffer for the multiplex PCR templates. The plasmid DNA of CDV and CIV was linearized with restriction enzyme (*Sac*I, New England Biolabs, Ipswich, MA) and the 3'overhang was conversed with the DNA polymerase (Klenow, Promega, Madison, WI). In vitro transcription was performed using Riboprobe in vitro Transcription Systems (Promega, Madison, WI) with T7 RNA Polymerase according to the manufacturer's recommendations. Remaining DNA was removed using RQ1 RNase-Free DNase (Promega, Madison, WI). The viral RNA was quantified using a spectrophotometer (GeneQuant II, Pharmacia, Uppsala, Sweden) and the copy number was calculated. The RNA was serially diluted 10-fold in DEPC treated water and used as templates for the following reverse transcription and multiplex PCR. The agarose gel and oligonucleotide microarray detection limits were then compared. Paired-samples *t*-test was used to evaluate the difference between agarose gel and microarray for clinical samples using SPSS 16.0 (IBM Corp, NY. USA).

3. Results {#sec0045}
==========

3.1. Uniplex and multiplex PCR {#sec0050}
------------------------------

Each uniplex PCR could specifically amplify its target pathogen and show the corresponding band on gels (Supplement Fig. 2). The multiplex PCR was successfully developed with the annealing temperature at 50 °C. The product sizes of CIV, *B. bronchiseptica*, CHV, *M. cynos* and CDV were 245 bp, 291 bp, 427 bp, 449 bp and 531 bp, respectively. CAV-2, CPIV-2 and CRCoV were not amplified as expected ([Fig. 1](#fig0005){ref-type="fig"} ). Different strains of CDVs could not be distinguished on gels.Fig. 1Multiplex PCR result of dog respiratory pathogens on an agarose gel. M: 100 bp ladder marker; 1: Influenza virus (245 bp); 2: *B. bronchiseptica* (291 bp); 3: CHV (427 bp); 4: *M. cynos* (449 bp); 5: CDV (531 bp); 6: CAV-2; 7: CPIV; 8: CRCoV; 9: Mixture of all pathogens containing 1--5. 10: Negative control.Fig. 1

3.2. Oligonucleotide microarray {#sec0055}
-------------------------------

Dog respiratory pathogens were tested using oligonucleotide microarrays following the multiplex PCR. All pathogens were unambiguously detected and differentiated with no cross-reactions found among the non-related probes ([Fig. 2](#fig0010){ref-type="fig"} ). The wild type and vaccine type CDVs were also well distinguished. CAV-2, CPIV-2, CRCoV and a nasal swab sample from a healthy dog were employed as negative controls. The results indicated good detection specificity among the selected pathogens and that the normal nasal flora would not bring about non-specific microarray signals.Fig. 2Detection and differentiation of dog respiratory pathogens using oligonucleotide microarrays. (A) Microarray map. The meaning of each probe and its detecting strains are shown in [Table 2](#tbl0010){ref-type="table"}. P: positive control. (B) The microarray detection results.Fig. 2

3.3. Detection limit test and comparison {#sec0060}
----------------------------------------

The detection limit results of agarose gel and the microarray after multiplex PCR are shown in [Fig. 3](#fig0015){ref-type="fig"} . The gel detection limits of CDV (wild type NTU311 strain), CIV, CHV, *B. bronchiseptica* and *M. cynos* were 50, 50, 100, 100 and 100 copy numbers, respectively. The microarray detection limits of CDV (wild type NTU311 strain), CIV, CHV, *B. bronchiseptica* and *M. cynos* were 10, 10, 100, 50 and 50 copy numbers, respectively. The CDV vaccine strains, including probe CDVV1 targeted Onderstepoort, Distemperoid, Lederle and BA strains and probe CDVV2 targeted N-CDV strain, displayed the same detection limit results as the wild strain (data not shown).Fig. 3Detection limit comparison on agarose gel and microarray. (A) CDV (wild type NTU311 strain). (B) Influenza virus. (C) CHV. (D) *B. bronchiseptic.* (E) *M. cyno.* M: 100 bp ladder marker; 1: 10^4^ copies; 2: 10^3^ copies; 3: 10^2^ copies; 4: 50 copies; 5: 10 copies; 6: 1 copy.Fig. 3

3.4. Clinical sample test {#sec0065}
-------------------------

Fifty-six nasal swab samples from 56 dogs showing respiratory signs were tested using the oligonucleotide microarray after multiplex PCR. Agarose gel results were compared concurrently ([Table 3](#tbl0015){ref-type="table"} ). The agarose gel and microarray detection results of certain representative samples are shown in supplement Fig. 3. The detection positive rates for the microarray and agarose gel were 59.0% (n = 33) and 41.1% (n = 23), respectively. The frequency of positive results was statistically different between these two methods (*p* value is 0.005 \< 0.05). The oligonucleotide microarray showed exceeding differentiation effectiveness. One sample was differentiated as a CDV traditional vaccine strain among the total 25 single CDV infection positive samples. Co-infections of CDV and influenza virus, CDV and CHV, CDV and *B. bronchiseptica* were demonstrated by microarrays but none were revealed by agarose gels.Table 3Pathogen detection and differentiation results of 56 clinical samples tested by agarose gel and oligonucleotide microarray after multiplex PCR.Table 3Detection methodNo. of pathogen typeNegativeCDV*B. bronchiseptica*CDV+ influenza virusCDV + CHVCDV+ *B. bronchiseptica*Agarose gel33230000Microarray2325^a^21^b^2^c^3^d^[^3][^4]

4. Discussion {#sec0070}
=============

The clinical signs caused by respiratory pathogens, including viruses and bacteria, are similar. Co-infections with multiple pathogens are also frequently seen ([@bib0025], [@bib0080], [@bib0100]) which makes differential diagnosis imperative to enact correct treatment. The introduction of live attenuated CDV vaccines in the 1950s and their extensive use have drastically reduced the CD incidence in dogs. However, CD outbreaks involving virulent viruses introduced into a partly immune population have still been observed ([@bib0095], [@bib0135]). Differentiation between wild type and vaccine type CDs is then necessary when performing CDV detection ([@bib0145], [@bib0165]). Based on the CDV H gene alignment and analysis of all CDV vaccines available in Taiwan, the CDV vaccine strains could be divided into two groups: traditional vaccine group (Onderstepoort strain, Distemperoid strain, Lederle strain and BA strain) and contemporary vaccine group (N-CDV strain, high homology to Vaccine X) ([@bib0040]). Three canine respiratory viruses (CDV, CRCoV and influenza virus) have been reported distinguished using multiplex PCR ([@bib0100]). Four canine respiratory RNA viruses and two DNA viruses have been reported detected using multiplex RT-PCR and multiplex PCR, respectively ([@bib0125]). Wild type and traditional CDV vaccine strains could be discriminated using PCR-restriction fragment length polymorphism ([@bib0165], [@bib0175]), and cotemporary vaccine strain was able to be distinguished using refractory mutation system-PCR amplification ([@bib0040]). However, no comprehensively integrated approach has ever been developed. Herein, an oligonucleotide microarray system was developed to simultaneously detect and differentiate clinical canine significant respiratory pathogens, including viruses, bacteria and traditional and contemporary CDV vaccine strains. The microarray signals were easily read with the naked eye requiring no additional reader equipment. The detection limit comparison and the clinical sample test findings demonstrated that the microarray had higher efficiency and sensitivity than the multiplex PCR-agarose gel method. The microarray CDV detection limit was 10 viral copies, which was even lower than the 23.2 copies using CDV hemi-nested RT-PCR ([@bib0075]). Although real time RT-PCR can achieve similar low detection limit for these respiratory pathogens ([@bib0005], [@bib0060], [@bib0115], [@bib0155], [@bib0170]), the machine cost is high. The microarray presented in this study compared to real time RT-PCR could be a feasibly alternative and especially preferable to the local under-equipped laboratories.

The microarray specificity also proved that no cross-reaction signals were observed among the unrelated probes. In the traditional approach, the agarose gel band needs to be cut and sequenced for confirmation of a doubtful result. However, the microarray accuracy could be ensured by omitting these steps since only complementary template-probe sequences hybrid and produce positive signals.

Although electrophoresis cost is 1.0 USD, it might increase to 9.0 USD if sequencing is needed for differentiation. Comparatively, the microarray cost is 3.0 USD but the array is reusable. No following gel imaging equipment and sequencing are demanded. The time cost from sample receipt to microarray readout is 4 h. However, it would take 3 days using traditional methods if sequencing was also included.

Probe CDVW1 was designed for the CDV wild type strains in Taiwan, Japan, South Korea and China. Probe CDVW2 and CDVW3 were for those in Japan, South Korea and China that CDVW1 cannot bind. However, CDVW2 and CDVW3 could not be tested in this study since these foreign strains were not available in Taiwan. Further experiments would be needed for CDVW2 and CDVW3 efficacy verification. In the microarray clinical sample tests, CDV, influenza virus, CHV and *B. bronchiseptica* were detected from the nasal swab samples but none of the *M. cynos* was captured. This might be due to the sampling method because *M. cynos* was only in the lower respiratory tract ([@bib0025]). The detection rate of *M. cynos* might be higher if the samples were taken from the lower respiratory tract, e.g. bronchial-alveolar lavage. Because RNA viruses would be under constant mutation over time, the microarray efficacy might decrease if the mutations occur to the primer or probe sites. However, the microarray functionality could be extended by recruiting new probes, which would make this device more applicable for meeting future practical needs.

Appendix A. Supplementary data {#sec0080}
==============================

The following are Supplementary data to this article:
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